Sumitomo Pharma Co., Ltd.
4506.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | ¥23,635,000 | -¥314,929,000 | -¥96,714,000 | ¥40,600,000 |
| Dep. & Amort. | ¥25,562,000 | ¥37,765,000 | ¥41,263,000 | ¥38,348,000 |
| Deferred Tax | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock-Based Comp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Change in WC | -¥18,770,000 | -¥95,847,000 | ¥34,878,000 | -¥33,733,000 |
| Other Non-Cash | -¥13,927,000 | ¥131,118,000 | ¥32,510,000 | -¥13,976,000 |
| Operating Cash Flow | ¥16,500,000 | -¥241,893,000 | ¥11,937,000 | ¥31,239,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -¥8,498,000 | -¥15,730,000 | -¥12,742,000 | -¥13,494,000 |
| Net Acquisitions | ¥1,458,000 | ¥8,605,000 | ¥30,172,000 | -¥3,701,000 |
| Inv. Purchases | -¥1,645,000 | -¥4,772,000 | -¥6,247,000 | -¥25,905,000 |
| Inv. Sales/Matur. | ¥108,491,000 | ¥34,499,000 | ¥10,068,000 | ¥19,472,000 |
| Other Inv. Act. | -¥52,000 | ¥10,434,000 | ¥31,168,000 | ¥5,350,000 |
| Investing Cash Flow | ¥99,754,000 | ¥33,036,000 | ¥52,419,000 | -¥18,278,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -¥112,485,000 | ¥84,000,000 | ¥65,499,000 | -¥4,931,000 |
| Stock Issued | ¥0 | ¥0 | ¥0 | ¥0 |
| Stock Repurch. | ¥0 | ¥0 | ¥0 | ¥0 |
| Dividends Paid | -¥3,000 | -¥2,792,000 | -¥11,125,000 | -¥11,126,000 |
| Other Fin. Act. | ¥3,652,000 | -¥3,357,000 | -¥201,191,000 | -¥5,369,000 |
| Financing Cash Flow | -¥108,836,000 | ¥77,851,000 | -¥146,817,000 | -¥21,426,000 |
| Forex Effect | -¥177,000 | ¥15,440,000 | ¥24,090,000 | ¥17,751,000 |
| Net Chg. in Cash | -¥5,931,000 | -¥114,431,000 | -¥59,506,000 | ¥9,286,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | ¥29,047,000 | ¥143,478,000 | ¥202,984,000 | ¥193,698,000 |
| End Cash | ¥23,116,000 | ¥29,047,000 | ¥143,478,000 | ¥202,984,000 |
| Free Cash Flow | ¥3,470,000 | -¥257,623,000 | -¥805,000 | ¥17,745,000 |